Teijin to start trial with first drug for lumbar hernia
This article was originally published in Scrip
Executive Summary
Japan's Teijin Pharma is preparing to begin a clinical trial with what it claims is the first non-surgical approach for the direct treatment of lumbar disc hernia - a recombinant version of the human matrix metalloproteinase enzyme.